Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Fate Therapeutics (NASDAQ: FATE), a clinical-stage biopharmaceutical company focused on developing iPSC-derived cellular immunotherapies for cancer and autoimmune diseases, has announced new employee inducement awards. On August 1, 2024, the company granted restricted stock units (RSUs) representing 34,200 shares of common stock to four newly-hired non-executive employees. These grants were approved by the Compensation Committee and issued under the company's Amended and Restated Inducement Equity Plan, in compliance with Nasdaq Listing Rule 5635(c)(4). The RSUs will vest over four years, with 25% vesting annually, contingent on continuous employment.
Fate Therapeutics (NASDAQ: FATE), un'azienda biofarmaceutica in fase clinica focalizzata sullo sviluppo di immunoterapie cellulari derivate da iPSC per il cancro e le malattie autoimmuni, ha annunciato nuovi premi per l'induzione dei dipendenti. Il 1° agosto 2024, l'azienda ha concesso unità di azioni restrittive (RSU) rappresentanti 34.200 azioni ordinarie a quattro nuovi dipendenti non esecutivi. Questi premi sono stati approvati dal Comitato per la Compensazione e rilasciati nell'ambito del Piano di Induzione Equitativa Modificato e Restituito dell'azienda, in conformità con la Regola 5635(c)(4) della Quotazione Nasdaq. Le RSU matureranno in quattro anni, con il 25% che matura annualmente, a condizione di un'occupazione continua.
Fate Therapeutics (NASDAQ: FATE), una empresa biofarmacéutica en etapa clínica centrada en el desarrollo de inmunoterapias celulares derivadas de iPSC para el cáncer y enfermedades autoinmunitarias, ha anunciado nuevos premios de inducción para empleados. El 1 de agosto de 2024, la empresa otorgó unidades de acciones restringidas (RSU) que representan 34,200 acciones ordinarias a cuatro nuevos empleados no ejecutivos. Estas concesiones fueron aprobadas por el Comité de Compensación y emitidas bajo el Plan de Inducción de Capital Modificado y Restablecido de la empresa, en cumplimiento con la Regla de Cotización 5635(c)(4) de Nasdaq. Las RSU se consolidarán en cuatro años, con el 25% consolidándose anualmente, sujeto a un empleo continuo.
Fate Therapeutics (NASDAQ: FATE)는 암 및 자가면역 질환을 위한 iPSC 유래 세포 면역 요법 개발에 집중하는 임상 단계의 생명공학 회사로, 새로운 직원 유인 보상을 발표했습니다. 2024년 8월 1일, 회사는 제한 주식 단위(RSU)로 34,200주에 해당하는 공통 주식을 4명의 신규 비임원 직원에게 부여했습니다. 이러한 보상은 보상 위원회의 승인을 받았으며, Nasdaq 상장 규칙 5635(c)(4) 준수에 따라 회사의 수정 및 재확인된 유인 자본 계획 아래 발행되었습니다. RSU는 4년에 걸쳐 분할 지급됩니다, 매년 25%가 분할 지급되며, 지속적인 고용 조건이 붙습니다.
Fate Therapeutics (NASDAQ: FATE), une entreprise bio-pharmaceutique en phase clinique axée sur le développement de thérapies immunitaires cellulaires dérivées d'iPSC pour le cancer et les maladies auto-immunes, a annoncé de nouvelles primes d'incitation pour les employés. Le 1er août 2024, l'entreprise a accordé unités d'actions restreintes (RSU) représentant 34 200 actions ordinaires à quatre nouveaux employés non exécutifs. Ces attributions ont été approuvées par le Comité de Rémunération et émises dans le cadre du Plan de Capital d'Induction Modifié et Restitué de l'entreprise, conformément à la Règle de Cotation 5635(c)(4) de Nasdaq. Les RSUs seront acquises sur une période de quatre ans, avec 25 % acquérant chaque année, sous réserve d'une continuité d'emploi.
Fate Therapeutics (NASDAQ: FATE), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf die Entwicklung von iPSC-abgeleiteten zellulären Immuntherapien für Krebs und Autoimmunerkrankungen konzentriert, hat neue Beschäftigtenanreize bekannt gegeben. Am 1. August 2024 gewährte das Unternehmen eingeschränkte Aktieneinheiten (RSUs), die 34.200 Stammaktien repräsentieren, an vier neu eingestellte nicht-executive Mitarbeiter. Diese Zuwendungen wurden vom Vergütungsausschuss genehmigt und im Rahmen des geänderten und neu gefassten Anreizkapitalplans des Unternehmens, im Einklang mit der Nasdaq-Listing-Regel 5635(c)(4), ausgegeben. Die RSUs werden über einen Zeitraum von vier Jahren fällig, wobei jährlich 25% fällig werden, unter der Bedingung einer kontinuierlichen Beschäftigung.
- Attraction of new talent with stock-based compensation
- Alignment of employee interests with company performance through RSUs
- Compliance with Nasdaq listing rules for inducement grants
- Potential dilution of existing shareholders' equity
- Increased share-based compensation expense over the vesting period
SAN DIEGO, Aug. 02, 2024 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases, today announced that on August 1, 2024 the Company granted restricted stock units (RSUs) representing 34,200 shares of its common stock to four newly-hired non-executive employees. The grants were approved by the Compensation Committee of the Company’s Board of Directors and granted under the Company’s Amended and Restated Inducement Equity Plan as an inducement material to the new employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4). The RSUs will vest over four years, with
About Fate Therapeutics’ iPSC Product Platform
The Company’s proprietary induced pluripotent stem cell (iPSC) product platform enables mass production of off-the-shelf, multiplexed-engineered cell products that are selectively designed, incorporate novel synthetic controls of cell function, and are intended to deliver multiple mechanisms of therapeutic importance to patients. Human iPSCs possess the unique dual properties of unlimited self-renewal and differentiation potential into all cell types of the body. The Company’s platform combines multiplexed engineering and single-cell selection of human iPSCs to create clonal master iPSC lines. Analogous to master cell lines used to mass produce biopharmaceutical drug products such as monoclonal antibodies, the Company utilizes its clonal master iPSC lines as a renewable cell source to manufacture multiplexed-engineered cell products which are well-defined and uniform in composition, can be stored in inventory for off-the-shelf availability, can be combined and administered with other therapies, and can potentially reach a broad patient population. As a result, the Company’s platform is uniquely designed to overcome numerous limitations associated with the manufacture of cell therapies using patient- or donor-sourced cells. Fate Therapeutics’ iPSC product platform is supported by an intellectual property portfolio of over 400 issued patents and 450 pending patent applications.
About Fate Therapeutics, Inc.
Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases. Using its proprietary iPSC product platform, the Company has established a leadership position in creating multiplexed-engineered iPSC lines and in the manufacture and clinical development of off-the-shelf, iPSC-derived cell products. The Company’s pipeline includes iPSC-derived natural killer (NK) cell and T-cell product candidates, which are selectively designed, incorporate novel synthetic controls of cell function, and are intended to deliver multiple therapeutic mechanisms to patients. Fate Therapeutics is headquartered in San Diego, CA. For more information, please visit www.fatetherapeutics.com.
Contact:
Christina Tartaglia
Precision AQ
212.362.1200
christina.tartaglia@precisionaq.com
FAQ
How many restricted stock units (RSUs) did Fate Therapeutics (FATE) grant on August 1, 2024?
What is the vesting schedule for the RSUs granted by Fate Therapeutics (FATE)?
How many new employees received RSU grants from Fate Therapeutics (FATE) in this announcement?
Under which Nasdaq rule were the inducement grants made by Fate Therapeutics (FATE)?
